49
2024-09-19 17:12:15
September 19, 2024 | 19.12
COUNT: 0 minutes
People with moderate to severe psoriasis now have a new treatment option. This is deucravacitinib, a first-in-class tyrosine kinase inhibitor drug for which the Italian Medicines Agency (Aifa) has approved reimbursement. The green light from Aifa came at the center of a press conference organized by Bristol Myers Squibb in Rome.
#Psoriasis #green #light #Aifa #reimbursement #deucravacitinib #moderate #severe #forms